鼠神经生长因子治疗后天麻痹性斜视疗效观察

Clinical efficacy of mouse nerve growth factor for treatment of acquired paralytic strabismus

摘要:

观察鼠神经生长因子治疗后天麻痹性斜视的临床疗效。方法将82 例后天麻痹性斜视患者随机分为鼠神经生长因子治疗组（治疗组）41 例和常规治疗组（对照组）41 例。对照组甲钴胺片口服0.5 mg，3 次/d，维生素B1 口服10 mg，3 次/d，治疗组加用肌肉注射鼠神经生长因子18μg，1 次/d，14 d为1 个疗程，治疗3 个疗程后观察疗效。结果痊愈26 例（63.41%），有效10 例（24.39%），无效5 例（12.20%），总有效率87.80%；对照组痊愈13 眼（31.71%），有效17 眼（41.46%），无效11 眼（26.83%），总有效率73.17%，两组疗效差异有统计学意义（ z=-2.807， p<0.05），且治疗组三棱镜斜视度改善程度优于对照组，差异有统计学意（p <0.05）。结论鼠神经生长因子治疗后天麻痹性斜视能提高临床疗效，改善症状，减轻斜视度，值得推广。

Abstract:

To observe the clinical curative effect of mouse nerve growth factor for treatment of acquired paralytic strabismus. Methods Eighty-two cases of acquired paralytic strabismus patients were randomly divided into mouse nerve growth factor treatment group (treatment group) and conventional treatment group (control group) with 41 cases in each group. The patients in the control group took Mecobalamin Tablets 0.5 mg 3 times a day, oral Vitamin B1 10 mg 3 times a day; the patients in the treatment group were added with intramuscular injection of 18 μg mouse nerve growth factor once a day, for 14 days as a course. The curative effect was observed after 3 courses of treatment. Results In the treatment group, 26 cases were cured (63.41%), the treatment was effective in 10 cases (24.39%) and invalid in 5 cases (12.20%), the total effective rate was 87.80%; in the control group, 13 eyes (31.71%) were cured, the treatment was effective for 17 eyes (41.46%) and invalid for 11 eyes (26.83%), the total effective rate was 73.17%; the curative effect of the two groupswassignificantlydifferent(z = -2.807,p< 0.05). And the improvement degree of prism strabismus in the treatment group was better than that in the control group, the difference was statistically significant (p < 0.05). Conclusions In the treatment of acquired paralytic strabismus, mouse nerve growth factor can significantly improve the clinical curative effect and is worth promoting.